Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 62259-92-1 | MDL No. : | MFCD22552967 |
Formula : | C15H17N3O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | HSHFWFQDSHKRIT-UHFFFAOYSA-N |
M.W : | 255.32 | Pubchem ID : | 135553026 |
Synonyms : |
|
Num. heavy atoms : | 19 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.33 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 78.55 |
TPSA : | 48.99 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.39 cm/s |
Log Po/w (iLOGP) : | 2.38 |
Log Po/w (XLOGP3) : | 0.66 |
Log Po/w (WLOGP) : | 0.95 |
Log Po/w (MLOGP) : | 1.68 |
Log Po/w (SILICOS-IT) : | 3.26 |
Consensus Log Po/w : | 1.79 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.17 |
Solubility : | 1.71 mg/ml ; 0.0067 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.26 |
Solubility : | 13.9 mg/ml ; 0.0543 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -5.04 |
Solubility : | 0.00233 mg/ml ; 0.00000914 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 2.55 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
95% | With sodium methylate In methanol at 25℃; for 20 h; Inert atmosphere | General procedure: To a solution of sodium methoxide (25 wt-percent in methanol) (67.6 mL, 296 mmol) and methanol (70 mL) at 25 °C was added formamidine acetate (11.00 g, 106 mmol) and then ethyl N-benzyl-3-oxo-4-piperidine carboxylate hydrochloride (25.16 g, 84 mmol). The resulting mixture was stirred at 25 °C for 20 h. The mixture was cooled to 0 °C. Water (90mL) was added, followed by the dropwise addition of acetic acid (6.05 mL, 106 mmol), and the reaction mixture was stirred at 25 °C for another 3 h. The mixture was reduced in volume under vacuum until most of the methanol had been removed. The suspension was filtered. The solids were washed with water and thendried under vacuum to afford 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one (16.10 g, 79 percent) as an off-white solid; LC/MS:m/z 242.06 (M + H)+, 0.598 min (method 12). 1H-NMR (500 MHz, CDCl3) δ12.61 (br s, 1 H), 7.99 (s, 1 H), 7.38-7.26 (m, 5 H),3.73 (m, 2 H), 3.50 (m, 2 H), 2.74 (m, 2 H), 2.66 (m, 2 H). |
77% | With sodium ethanolate In ethanol for 16 h; Heating / reflux | Example 51Preparation of Compounds 211, 215, 216, 225, 226 and 231Compounds 211, 215, 216, 225, 226 and 231 were prepared using the method set forth below. <n="193"/>Step A - Synthesis of7-benzyl-2-methyl-5,6, 7,8-tetrahydro-3H-pyrido[3,4-d]pyrimidin-4-oneTo a solution of l-benzyl-3-oxo-piperidine-4-carboxylic acid ethyl ester hydrochloride (5.0 g, 16.8 mmol) in 80 mL ethanol was added acetamidine hydrochloride (2.4 g, 25.2 mmol) followed by sodium ethoxide (21percent in ethanol, 10.6 mL, 33.6 mmol). The resulting reaction was heated to reflux and allowed to stir at this temperature for 16 hours. The reaction was then cooled to room temperature, diluted with dichloromethane, and the organic phase was washed with water and brine, dried and concentrated in vacuo, the resulting residue was purified using flash column chromatography (5percent methanol in dichloromethane) to provide 7-benzyl-2- methyl-5,6,7,8-tetrahydro-3H-pyrido[3,4-d]pyrimidin-4-one in 77percent yield. |
95% | With sodium ethanolate In ethanol; water; acetic acid | Step A: 7-Benzyl-2-methyl-5,6,7,8-tetrahydro-3H-pyrido[3,4-d]pyrimidin-4-one A solution of sodium ethoxide in ethanol was prepared by addition of sodium metal (5.7 g, 247 mmol) to absolute ethanol (141 mL). After the sodium metal had all dissolved, ethyl 1-benzyl-3-oxo-4-piperidine carboxylate hydrochloride (21 g, 70.5 mmol) was added followed by acetamidine hydrochloride (13.3 g, 141 mmol). This mixture was stirred at reflux for 1 h, cooled to room temperature, and concentrated. The residue was dissolved in a minimum amount of water and the pH was adjusted to about 7 with glacial acetic acid. The resulting yellow precipitate was filtered, washed with water (3*), air-dried for 2 h, then vacuum-dried overnight to provide 17.1 g (95percent) of the title compound of Example 86, Step A as a yellow solid. 1H NMR (CDCl3, 250 MHz) δ7.35-7.25 (c, 5H), 3.70 (s, 2H), 3.42 (s, 2H), 2.73-2.64 (c, 2H), 64-2.60 (c, 2H), 2.41 (s, 3H); MS (APCI) 256 (MH+). |
[ 62458-96-2 ]
7-Benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one
Similarity: 0.91
[ 1290541-46-6 ]
(E)-3-Benzyl-2-(2-(pyridin-3-yl)vinyl)quinazolin-4(3H)-one
Similarity: 0.78
[ 109229-22-3 ]
6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one
Similarity: 0.78
[ 18184-75-3 ]
6-Benzyl-5,7-dihydro-5,7-dioxopyrrolo[3,4-b]pyridine
Similarity: 0.71
[ 342417-01-0 ]
6-(4-Methylpiperazin-1-yl)-4-(o-tolyl)nicotinamide
Similarity: 0.69
[ 62458-96-2 ]
7-Benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one
Similarity: 0.91
[ 1290541-46-6 ]
(E)-3-Benzyl-2-(2-(pyridin-3-yl)vinyl)quinazolin-4(3H)-one
Similarity: 0.78
[ 109229-22-3 ]
6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one
Similarity: 0.78
[ 1015474-32-4 ]
3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
Similarity: 0.76
[ 63234-80-0 ]
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
Similarity: 0.76
[ 62458-96-2 ]
7-Benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one
Similarity: 0.91
[ 109229-22-3 ]
6-Benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one
Similarity: 0.78
[ 93076-03-0 ]
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride
Similarity: 0.76
[ 63234-80-0 ]
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
Similarity: 0.76
[ 19178-25-7 ]
Pyrido[3,4-d]pyrimidin-4(3H)-one
Similarity: 0.75